Printer Friendly

NIH Awards BioAxone BioSciences USD 1.5m SBIR Grant.

M2 PHARMA-August 4, 2017-NIH Awards BioAxone BioSciences USD 1.5m SBIR Grant

(C)2017 M2 COMMUNICATIONS

- The National Institutes of Health, Small Business Innovation Research, and National Institute of Neurological Disorders and Stroke, has awarded Cambridge, Massachusetts-based neurotrauma and neurovascular disorders specialist BioAxone BioSciences, Inc. a USD 1.5m grant, the third year installment to continued research into BioAxone's first-in-class selective Rho Kinase 2 (ROCK2) inhibitor, BA-1049, a drug in development to treat cerebral cavernous malformations (CCM), the company said.

The award was based on research and development milestones achieved by BioAxone.

CCM is a serious genetic disease where patients have a lifetime risk of brain hemorrhage from vascular malformations in the brain in which endothelial cells form single or multiple cystic brain lesions that leak and may cause seizure, hemorrhagic stroke, and neurological deficits.

Inherited cases of CCM are caused by mutation in one of the 3 CCM genes (CCM1, CCM2 and CCM3) and CCM loss of function results in the overactivation of ROCK2, the target of BA-1049 development.

In preclinical experiments BA-1049, a first-in-class oral inhibitor of Rho kinase 2 (ROCK2), has shown promise to repair the leaky endothelial cell barrier and potentially to reverse progression of disease. BioAxone is progressing key non-clinical IND enabling studies with this small molecule.

BioAxone BioSciences is developing innovative drugs to restore neurological function for patients with spinal cord injuries, vascular malformations in the central nervous system, and glaucoma.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Aug 4, 2017
Words:248
Previous Article:NIAID Awards Integrated BioTherapeutics USD 6.6m Grant for Development of Pan-Ebolavirus Vaccine in Collaboration with The Scripps Research Institute.
Next Article:AgeX Therapeutics Secures USD 10m Funding to Develop Age-Related Disease Treatments.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters